BIC China 2026 | Sharing Insights on New Industry Trends

From August 20 to 21, 2026, the 5th BIC China Biopharmaceutical Industry Chain Development Conference was held in Hangzhou. Hosted by the Zhejiang Pharmaceutical Industry Association and the Zhejiang Provincial Drug MAH Transformation Platform, and organized by the Hangzhou (Innovation) Institute of Medicine of China Pharmaceutical University and the Qiantang MAH Institute, the conference drew more than 1,500 delegates from regulatory authorities, research institutes, pharmaceutical companies and industry service organizations, with over 1,000 companies represented. HOPE sent a team to take part in the full two-day program and received visiting clients and partners at Booth A24.

I. Conference Overview

The two-day conference featured a main forum and a number of thematic forums, covering drug regulatory reform, innovative drug R&D, AI-driven pharmaceutical development, the inheritance and innovation of traditional Chinese medicine, CDMO, drug formulation, BD and overseas expansion for innovative drugs, peptide and oligonucleotide drugs, and cell and gene therapy. The industry trends that emerged over the two days centered on the following areas:

First, drug regulation continues to extend across the full product lifecycle. Clinical trial inspections, quality management for segmented manufacturing, and full-chain risk control and post-marketing supervision under the MAH system made up the core of the conference's regulatory track.

Second, the development logic of innovative drugs is becoming more systematic. Considerable attention was given to the coordination among registration review, clinical value assessment and medical insurance reimbursement, as industry competition extends from individual R&D stages to full-chain capabilities.

Third, AI-driven pharmaceutical development is moving faster toward real-world application. Discussion at the related forums shifted from technological concepts to data governance, computing infrastructure, and specific use cases across R&D, manufacturing and marketing.

Fourth, the paths of specialized segments are becoming clearer. The thematic forums held on August 21 — on high-quality CDMO development, drug formulation, BD and overseas expansion for innovative drugs, peptides and oligonucleotides, and cell and gene therapy — each explored the technological directions and internationalization paths of their respective fields.

II. Outcomes of Our Participation

A precise read on regulatory trends. The Drug Regulation and Innovation Forum's interpretation of the deepening MAH system and of the new rules on contract and segmented manufacturing provided practical reference for our project initiation and compliance management work.

Efficient connection of industry chain resources. During the conference, our team established preliminary cooperation intentions with API suppliers, formulation companies, innovative drug developers and investment institutions, further linking the key nodes of “R&D — manufacturing — commercialization”.

Continued growth in brand influence. Through a concentrated presence at an industry event attended by more than a thousand companies, HOPE further consolidated its brand image as “a trusted partner in chemical drug R&D”.

III. Closing Remarks

The conference brought into focus an industry trend in which regulation, technology, clinical practice and industrialization advance in coordination. HOPE will take this participation as an opportunity to further deepen its professional capabilities in chemical drug R&D and its collaboration across the industry chain, working with partners to drive high-quality development of the industry.